Pollak V E, Dosekun A K
Am J Kidney Dis. 1982 Jul;2(1 Suppl 1):170-7.
Survival of patients with SLE and renal disease has improved in the past 25 yr. There are numerous variables in patients with SLE, and many factors are important in determining outcome. The precise role of any therapeutic regimen in improving survival is unproven. Patients with SLE with normal kidneys, with mesangial changes or with membranous glomerulonephropathy do well whatever treatment is used. Focal and diffuse proliferative glomerulonephritis has a poor prognosis without treatment. Prednisone treatment appears to have improved the survival, but it is probable that treatment with prednisone alone may be less effective than a regimen in which it is combined with cyclophosphamide or nitrogen mustard.
在过去25年中,系统性红斑狼疮(SLE)合并肾脏疾病患者的生存率有所提高。SLE患者存在众多变量,许多因素对预后至关重要。任何治疗方案在提高生存率方面的确切作用尚未得到证实。肾脏正常、有系膜改变或膜性肾小球肾炎的SLE患者,无论采用何种治疗方法,预后都较好。局灶性和弥漫性增殖性肾小球肾炎未经治疗预后较差。泼尼松治疗似乎提高了生存率,但单独使用泼尼松治疗可能不如与环磷酰胺或氮芥联合使用的方案有效。